Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:CRON TSE:ITH NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsCRONCronos Group$2.58-0.4%$2.33$1.60▼$2.77$987.86M1.131.91 million shs1.13 million shsITHInternational Tower Hill MinesC$2.05-5.5%C$1.76C$0.60▼C$2.29C$426.16M0.91461531,249 shs30,900 shsTLRYTilray Brands$1.19-2.5%$0.94$0.35▼$1.87$1.31B2.0342.84 million shs35.85 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+65.24%CRONCronos Group+1.57%+1.57%+9.28%+35.60%+15.63%ITHInternational Tower Hill Mines-3.13%+2.36%+30.72%+76.42%+178.21%TLRYTilray Brands+3.39%+7.02%+18.45%+218.29%-32.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsCRONCronos Group$2.58-0.4%$2.33$1.60▼$2.77$987.86M1.131.91 million shs1.13 million shsITHInternational Tower Hill MinesC$2.05-5.5%C$1.76C$0.60▼C$2.29C$426.16M0.91461531,249 shs30,900 shsTLRYTilray Brands$1.19-2.5%$0.94$0.35▼$1.87$1.31B2.0342.84 million shs35.85 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+65.24%CRONCronos Group+1.57%+1.57%+9.28%+35.60%+15.63%ITHInternational Tower Hill Mines-3.13%+2.36%+30.72%+76.42%+178.21%TLRYTilray Brands+3.39%+7.02%+18.45%+218.29%-32.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/ACRONCronos Group 0.00N/AN/AN/AITHInternational Tower Hill Mines 0.00N/AN/AN/ATLRYTilray Brands 2.33Hold$1.9460.79% UpsideCurrent Analyst Ratings BreakdownLatest ITH, TLRY, CARA, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.50 ➝ $2.007/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CRONCronos Group$117.61M8.42$0.00 per share5,480.10$2.90 per share0.89ITHInternational Tower Hill MinesN/AN/AC$0.10 per share22.50C$0.29 per shareN/ATLRYTilray Brands$821.31M1.61$0.15 per share8.16$1.40 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ACRONCronos Group$41.08M$0.0551.7086.17N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/ATLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest ITH, TLRY, CARA, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/9/2025Q1 2026TLRYTilray Brands-$0.03N/AN/AN/A$205.75 millionN/A8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CRONCronos GroupN/A24.6523.53ITHInternational Tower Hill MinesN/A10.3730.48TLRYTilray Brands0.202.461.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CRONCronos Group8.71%ITHInternational Tower Hill Mines6.04%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CRONCronos Group6.90%ITHInternational Tower Hill Mines0.51%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCRONCronos Group450382.89 million356.47 millionOptionableITHInternational Tower Hill Mines220207.89 millionN/ANot OptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableITH, TLRY, CARA, and CRON HeadlinesRecent News About These CompaniesBest Cannabis Stocks To Consider - September 17thSeptember 17 at 1:09 PM | marketbeat.comTilray stock price sits and waits for Trump cannabis reschedulingSeptember 17 at 11:02 AM | invezz.comITilray Brands Inc. Unveils BC Selects: A New Line of Limited-Edition Premium Cannabis from Broken CoastSeptember 17 at 7:50 AM | quiverquant.comQBroken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain “Sprits 26”, Elevates Craft Portfolio with Modern Blue Dream ReleaseSeptember 17 at 7:00 AM | globenewswire.comTilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 17 at 4:17 AM | marketbeat.comTilray Brands (TLRY) Is Down 5.9% After DOJ Rule SetbackSeptember 16 at 2:11 PM | finance.yahoo.comBest Cannabis Stocks To Watch Now - September 16thSeptember 16 at 1:25 PM | marketbeat.comBreckenridge Brewery Awarded Silver Certification By The Colorado Green Business NetworkSeptember 16 at 10:50 AM | insidermonkey.comBest Canadian Marijuana Stocks for Traders and Investors Right NowSeptember 16 at 10:00 AM | marijuanastocks.comMHop Valley Brewing and Oregon Athletics Announce the Launch of Dang Green IPA, the First Official Craft Beer for the Oregon DucksSeptember 16 at 7:00 AM | globenewswire.comBest Cannabis Stocks To Keep An Eye On - September 15thSeptember 15 at 1:04 PM | marketbeat.comTop Cannabis Stocks To Watch Today - September 14thSeptember 15 at 1:00 PM | marketbeat.comCannabis Stocks To Research - September 13thSeptember 14 at 1:07 PM | marketbeat.comPromising Cannabis Stocks To Consider - September 12thSeptember 13, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Up - Should You Buy?September 13, 2025 | marketbeat.comCannabis Stocks Worth Watching - September 11thSeptember 12, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - Here's What HappenedSeptember 12, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 3.9% - Should You Sell?September 11, 2025 | marketbeat.comPromising Cannabis Stocks To Follow Today - September 10thSeptember 11, 2025 | marketbeat.comPot Stocks Rallied Hard in August: Is There More to Come?September 10, 2025 | msn.comTilray Brands (NASDAQ:TLRY) Trading Up 1.3% - Here's WhySeptember 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Broadcom Named in Apple’s $100B U.S. Investment PlanBy Leo Miller | August 22, 2025Why BitMine’s Massive Discount Could Signal a Major OpportunityBy Jeffrey Neal Johnson | August 21, 2025Tesla's Breakout: Why This Rally Looks Far From OverBy Sam Quirke | August 20, 2025Jackson Hole 2025: Fed’s Signal Could Shift Stocks FastBy Chris Markoch | August 20, 2025ITH, TLRY, CARA, and CRON Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Cronos Group NASDAQ:CRON$2.58 -0.01 (-0.39%) Closing price 04:00 PM EasternExtended Trading$2.61 +0.03 (+1.16%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.International Tower Hill Mines TSE:ITHC$2.05 -0.12 (-5.53%) As of 03:59 PM EasternInternational Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an advanced stage exploration project namely the Livengood Gold Project. It is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska mental health trust, a number of smaller private mineral leases, Alaska state mining claims purchased or located by the company and patented ground held by the company.Tilray Brands NASDAQ:TLRY$1.19 -0.03 (-2.46%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
